Weight-Loss Drugs Show Potential Beyond Obesity Treatment in HIV, Cancer, and Other Conditions Drugs initially developed for diabetes treatment, such as Ozempic, Mounjaro, and Wegovy, are now being studied for their potential to address a wide range of health conditions beyond weight loss. Medical researchers in the Netherlands have reported that these medications may offer benefits for diseases including cancer, cardiovascular disorders, arthritis, sleep apnea, and HIV, according to recent studies and clinical observations. The findings suggest that the drugs’ effects extend beyond their primary use for managing obesity and diabetes, raising new possibilities for treating conditions traditionally linked to metabolic and inflammatory processes. The medications, which work by suppressing appetite and reducing glucose levels, have already revolutionized obesity treatment. However, their broader applications are now under investigation. Researchers highlight that obesity is a significant risk factor for 13 types of cancer, as well as cardiovascular disease and joint disorders. In these cases, weight reduction is often considered a critical factor in lowering disease risk. Liesbeth van Rossum, an internist-endocrinologist specializing in obesity research, noted that while these drugs have primarily been used to address the symptoms of obesity, there is growing interest in treating obesity itself as a root cause of related conditions. “For a long time, we have only treated the diseases caused by obesity,” she said. “Now, an era is coming in which we can increasingly treat obesity itself, which lies as the driving factor behind those diseases.” Beyond weight loss, scientists are exploring the potential direct biological effects of these drugs.#ozempic #wegovy #mounjaro #liesbeth_van_rossum #casper_rokx
Charles Barkley’s Weight Loss and Ill-Fitting Suits Spark Online Memes Charles Barkley, the 63-year-old former NBA star, has undergone a dramatic weight loss of 85 pounds over the past few years, transforming his physique significantly. However, his recent appearances have drawn attention for his ill-fitting suits, which have become a source of humor and criticism online. Despite his physical transformation, Barkley’s wardrobe choices have raised eyebrows, with many noting that his suits appear oversized and unflattering. The 11-time NBA All-Star, who was listed at 250 pounds throughout his professional career, gained over 100 pounds by 2020, reaching a weight of more than 350 pounds. His weight loss journey began in 2023 with the use of GLP-1 medications, including Mounjaro and Zepbound, and he has since become the face of Ro, a pharmaceutical company. These drugs, originally designed to manage diabetes, work by mimicking a hormone released after eating, which helps regulate blood sugar levels, slow stomach emptying, and promote a feeling of fullness. While primarily intended for diabetes treatment, many users, including Barkley, have adopted them for weight management, alongside improved diet and increased physical activity. Barkley’s recent return as a March Madness analyst highlighted the issue. During a studio appearance, his suit was described as baggy, with sleeves that hung loosely and a head-to-body proportion that appeared disproportionate. Social media users quickly took notice, comparing his look to a child wearing his father’s clothes. Memes and tweets mocked the situation, with one user writing, “People thought he looked like a kid wearing their dad’s suit.” Another joked, “Why does Charles Barkley look like a child wearing their father’s suit? Someone get this man a tailor 😭 #MarchMadness.#charles_barkley #zepbound #march_madness #mounjaro #ro_pharmaceuticals
Charles Barkley, a celebrated NBA icon, has evolved into a prominent figure during the NCAA Tournament each March, known for his humorous commentary and candid reactions. This year, however, fans have taken notice of a noticeable change in his physique—Barkley appears significantly leaner than in recent years. Barkley has openly discussed his weight-loss journey, revealing that he shed 62 pounds since 2023. He attributed this transformation to a weekly injection of Mounjaro, a medication containing tirzepatide, alongside regular physical activity. He emphasized that the drug helped regulate his appetite and improve long-standing habits, which he had struggled to manage for years. A pivotal moment in his health shift came after a blunt warning from his doctor, which motivated him to prioritize his well-being. Barkley has consistently framed his goals as living longer and feeling better, rather than focusing solely on appearance. However, his journey has not been without challenges. In 2025, he revealed that a previous attempt to use a GLP-1 medication led to significant weight loss but was interrupted by supply issues, resulting in weight regain. This experience prompted him to restart his health efforts with Ro, a company collaborating with him. Barkley’s story resonates because it reflects the complexities of weight loss. His progress has been uneven, marked by periods of success and setbacks, which makes his journey relatable to many. The visibility of his transformation has also highlighted the role of GLP-1 drugs, which mimic hormones like GLP-1 and GIP to suppress appetite, slow digestion, and reduce hunger signals. These medications, when combined with lifestyle changes, can aid weight loss.#nba #charles_barkley #march_madness #mounjaro #ro
